XML 24 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue
 12 Months Ended
Dec. 31, 2023
Revenue Recognition [Abstract]  
Revenue Revenue
The Company recorded the following revenues for the years ended December 31 (in thousands):
Years Ended December 31,
202320222021
ORLADEYO:
U.S.$288,361 $226,358 $117,836 
Outside of U.S.37,629 25,275 4,719 
Total ORLADEYO325,990 251,633 122,555 
Other revenues5,422 19,194 34,615 
Total revenues$331,412 $270,827 $157,170 
ORLADEYO revenues represent total revenues from product sales, collaborative revenues and royalties. Royalty revenue from sales of ORLADEYO in Japan by the Company’s collaborative partner, Torii, were $2,178, $1,944, and $690 for the years ended December 31, 2023, 2022, and 2021 respectively.
Other revenues primarily relate to the Company’s product sales and royalties for peramivir injection (RAPIVAB/RAPIACTA/PERAMIFLU), and for the years ended December 31, 2022 and 2021, galidesivir development contracts with BARDA/HHS and NIAID/HHS. Other revenues for the year ended December 31, 2021 also includes milestone revenue of $15,000 upon receipt from the Japanese National Health Insurance System (“NHI”) of a reimbursement price approval for ORLADEYO.